Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nerofe+ldDox releases c-Jun from nuclear ST2 to reprogram the immune microenvironment in mtKRAS tumors.

Oncotarget - 24 Dec 2025

Ohana Joel, Sandler Uziel, Weinberg Benjamin A, Liu Stephen, Devary Yoram

Abstract excerpt

BACKGROUND/OBJECTIVES: Mutant KRAS (mtKRAS) tumors are highly immunosuppressive, largely through secretion of IL-10 and TGF-β2, which prevent immune cell infiltration. Nerofe (dTCApFs), a peptide derivative of Tumor Cell Apoptosis Factor, induces endoplasmic reticulum stress and modulates immune signaling through the T1/ST2 receptor, which is overexpressed in mtKRAS tumors. We evaluated whether combining Nerofe...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Doxorubicin

Share to Mutation

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins c-jun

Share to Proto-Oncogene Proteins p21(ras)

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 41459907
DOI: 10.18632/oncotarget.28820
PMCID: PMC12750723

Genes

KRAS
CD4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nerofe+ldDox releases c-Jun from nuclear ST2 to reprogram the immune microenvironment in mtKRAS tumors.PMID 41459907Read ↗

Current advances in immunotherapy for KRAS-Mutant pancreatic cancer.Semantic proximity Read ↗

Combined MEK and STAT3 inhibition reprograms stromal inflammation to overcome immunotherapy resistance in pancreatic cancerSemantic proximity Read ↗

Therapeutic Blockade of Type 2 Cytokines and PD1 Unleashes Anti-Tumor Immunity Through Coordinated Reprogramming of Innate and Adaptive Immune SurveillanceSemantic proximity Read ↗

Selective Targeting uPAR-driven Neutrophil Extracellular Traps Functional Clusters to Attenuate Tumor Progression and Enhance the Response to Immunotherapy in Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

Targeting tumor-intrinsic TAK1 triggers anti-tumor immunity and sensitizes pancreatic cancer to checkpoint blockadeSemantic proximity Read ↗

NRF2 Participates in the Suppressive Tumor Immune Microenvironment of KRAS/KEAP1 Co-Mutant Non-Small Cell Lung Cancer by Inhibiting the STING PathwaySemantic proximity Read ↗

Enhanced Complement Expression in the Tumor Microenvironment Following Neoadjuvant Therapy: Implications for Immunomodulation and Survival in Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer.Semantic proximity Read ↗

Distinct small molecule inhibitors of Kras specifically prime CTLA4 blockade therapy to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancerSemantic proximity Read ↗

Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer.Semantic proximity Read ↗

A stress-NRF2 response axis polarises tumor macrophages and undermines immunotherapySemantic proximity Read ↗

An in situ immunogenicity-amplifying payload delivery system for immunotherapy of Kirsten rat sarcoma viral oncogene homolog-mutant cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.